D 43787

Drug Profile

D 43787

Latest Information Update: 18 Jul 2006

Price : $50

At a glance

  • Originator Muro Pharmaceutical; Viatris
  • Class Amino acids; Antiasthmatics; Indoles
  • Mechanism of Action Cyclophilin modulators; T cell activation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Asthma; Rheumatoid arthritis

Most Recent Events

  • 18 Jul 2006 No development reported - Preclinical for Asthma in USA (unspecified route)
  • 18 Jul 2006 No development reported - Preclinical for Rheumatoid arthritis in Germany (unspecified route)
  • 18 Jul 2006 No development reported - Preclinical for Asthma in Germany (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top